The abbreviations used are: topo I, topoisomerase I; topo II, topoisomerase II; CPT, camptothecin; ALT, alternative lengthening of telomeres; ICT bioassay, in vivo complex of topoisomerase bioassay; TRF, terminal restriction fragment. Here we examined the activity of topoisomerase I at telomeric repeats to determine whether telomere structures are targets for DNA damage. We show that topoisomerase I is catalytically active in cleaving the G-rich telomeric strand in vitro in the presence of camptothecin but not in cleaving the C-rich strand. The topoisomerase I cleavage site is 5'TT*AGGG3' (cleavage site marked by the asterisk). We also show that endogenous topoisomerase I can access telomeric DNA in vivo and form camptothecin-dependent covalent complexes. Therefore, each telomeric repeat represents a potential topoisomerase I cleavage site in vivo. Since telomere structures are comprised of a large number of repeats, telomeres in fact represent a high concentration of nested topoisomerase I sites. Therefore, more telomeric DNA damage by camptothecin could occur in cells with longer telomeres when cells possess equivalent levels of topoisomerase I. The evidence presented here suggests that DNA damage at telomeric repeats by topoisomerase I is a prominent feature of cell killing by camptothecin and triggers camptothecin-induced apoptosis.
INTRODUCTION
Eukaryotic topoisomerase I (topo I) 1 participates in a variety of DNA transactions to reduce or modulate torsional stress in the template (reviewed in ref [1] [2] [3] . The process involves passing an intact DNA strand through an enzyme/DNA cleavage gate followed by resealing (1, 2) . The single-stranded DNA cleavage is a transesterification reaction and involves the concurrent formation of a transient covalent bond between the active site tyrosine in topo I and the 3'-phosphoryl end of the broken DNA strand. Under normal physiological conditions, the cleavage/religation reaction strongly favours the resealed state of DNA thereby minimizing DNA breakage; however, topo I active poisons, such as camptothecin (CPT) and its derivatives, stabilize covalent complex formation leading to accumulated DNA breaks in the genome (4).
The efficacy of topo I poisons as anticancer agents may be related to the fact that drug-mediated cleavage complexes stabilized during S phase are much more toxic than those stabilized during G 1 and G 2 phases (5, 6) . During DNA replication, the replication fork is thought to collide with the trapped covalent cleavable complexes, resulting in a double-strand break and eventually cell death (7, 8) . Since tumor cells typically have a higher mitotic index relative to normal, surrounding tissues, cell cycle considerations are likely to be important in selectivity of CPT;
however, other tumor selectivity mechanisms may also be operable. 6 incubated at 37°C for 30 min, and terminated by addition of SDS to 0.5% followed by incubation with 50 µg/ml proteinase K at 56°C for 30 min. The DNA cleavage products were precipitated with ethanol, resolved by denaturing 8% polyacrylamide gel electrophoresis, and identified by means of comparison with the Maxam-Gilbert sequencing ladders (21) .
Cell Culture-The human cervical cancer cell line HeLa and the human prostate carcinoma cell line DU145 were cultured in RPMI 1640 medium, and the human fibrosarcoma cell line HT1080 and the human vulval carcinoma cell line A431 were cultured in Dulbecco's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin in 5% CO 2 at 37°C.
In Vivo Complex of Topoisomerase (ICT) Bioassay-Topo I/DNA covalent complexes
were trapped by an antibody-based ICT bioassay as previously described (23) (24) (25) . Briefly, cells were treated with CPT at indicated concentrations for 1 hr at 37°C in serum-free medium. The cells were directly lysed and overlayed onto CsCl step gradients as described in detail elsewhere (23) . Fractions were collected from the bottom, and the DNA peak fractions were localized by determining the absorbance at 260 nm. Each fraction (50 µl) was applied to
Hybond ECL membrane (Amersham Pharmacia Biotech) in a slot blot device. The human topo I antibody was incubated with membranes, and the immunoblot signals were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech). 7 were washed and digested with proteinase K (50 µg/ml) at 56°C for 30 min. DNA samples were then applied to Hybond N + membrane in a slot blot device for Southern blotting. The membrane was hybridized with a human telomeric probe prepared by random-prime labeling of a BamHIPstI fragment from plasmid pHT-600 (21) . To detect topo I cleavage on telomeric repeats in vivo, SDS-K + precipitates and supernatants were resolved by electrophoresis in an alkaline 1% agarose gel followed by Southern blotting using (CCCTAA) 4 oligonucleotide as a probe.
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RESULTS

Topo I Cleavages on Telomeric Repeats
In Vitro-CPT stimulates DNA single-strand breaks by preferentially trapping a subset of the topo I cleavage sites (9) (10) (11) . Since DNA sequence selectivity is consistent with the ubiquity of function of topo I in the genome, we compared the enzyme consensus sequence data with various genomic sequences. This analysis revealed that the human telomeric repeat sequence displays considerable homology to the consensus sequence for vertebrate topo I (9, 12) . To examine topo I cleavage activity directly, we performed the topo I cleavage reactions on a linear, 3' end-labeled DNA target containing various lengths of telomeric repeats. Cleavage sites in the absence and presence of CPT were analyzed on a sequencing gel along with chemical sequencing ladders. As shown in Fig. 1A , a single topo I
cleavage was detected at each repeat on G-rich strand. In addition, the number of topo I cleavage sites is commensurate with the number of telomeric repeats in the target sequence (pHT-G3 showed 3 cleavages, and pHT-6 showed 6, etc.). Since telomeric DNA is a tandem array of the 5'TTAGGG3' and a single topo I cleavage occurs every six base pairs (Fig. 1B) , a highly polymerized telomere may constitute a rather high affinity topo I cleavage environment in the human genome. We also note that cleavages were strongly or totally dependent on the presence of CPT. Topo I cleavage was not detected in reactions lacking drug or containing 100 µM coralyne, a different but potent inducer of topo I/DNA cleavage complex. The concentrations of CPT and coralyne used in reactions were sufficient to induce topo I cleavages in other sequences (data known shown).
We next determined whether the opposite (C-rich) strand possesses a topo I cleavage site.
There were no topo I cleavages detected within the 5'CCCTAA3' repeat sequences (Fig. 2, left panel). When the duplex DNA containing both G-rich and C-rich repeats on the same strand was used, topo I cleavage was observed only in the region of 5'TTAGGG3' repeats, and we again observed no cleavage in the 5'CCCTAA3' repeats ( Fig. 2, right (23) . This method has been successfully used to directly evaluate the action of endogenous topo I on genomic DNA in the presence of the enzyme poisons (25) and in response to endogenous DNA damage (27, 28) . In the presence of topo I poisons, the breaks are stabilized and a covalent topo I/DNA complex can be trapped upon addition of protein denaturants.
Genomic DNA was purified from HeLa cells that were untreated or treated with CPT using a preparative step CsCl gradient that resolves free protein (1.3 g/cc) from DNA (1.7 g/cc) (Fig.   3A ). Various gradient fractions were subjected to immunoblotting analysis with a topo I antibody. Topo I was consistently detected in the DNA peak fractions of CPT-treated cells, but was not detected in the DNA fractions of untreated control cells (Fig. 3B ). These data establish that topo I/DNA complexes are present in DNA fractions of the preparative CsCl gradient from CPT-treated cells.
To determine whether the telomeric DNA was associated with topo I, the DNA peak fractions from CPT-treated or untreated HeLa cells were recovered, dialyzed and digested with
HaeIII, followed by SDS-K + precipitation (26) . SDS-K + treatment separates topo I-bound DNA (precipitate) from unbound free DNA (supernatant). As an internal control, SDS-K + precipitation was performed on proteinase K-treated DNA. Proteinase K digestion will remove topo I from the DNA to reveal non-specific trapping of naked DNA in the SDS-K + precipitates.
The DNA was recovered from the various SDS-K + fractions and was loaded onto a slot blot device that was subsequently analysed by Southern blotting using a probe derived from telomeric repeats. In the absence of drug, no signal was detected in the SDS-K + precipitates, consistent with the result that the DNA peak fractions did not contain topo I in the untreated sample. Furthermore, the SDS-K + supernatant and precipitate signals were not affected by proteinase K digestion ( To test the specificity of the telomeric DNA detected in the SDS-K + precipitates, the membranes were stripped and rehybridized with an Alu probe. As shown in Fig. 5C , all the SDS-K + precipitations brought down similar amounts of Alu DNA, regardless of telomere length. Only a small fraction (ranging from 1.6% to 2.3%) of total Alu DNA was involved in the formation of topo I/Alu DNA complexes in the presence of CPT. These results suggest that enrichment of telomeric DNA by CPT treatment in the SDS-K + precipitates is specific, and that all cell lines examined possess nearly equivalent levels of topo I.
Topo I Cleavage on G-rich Telomeric Strand
In Vivo-To verify that topo I was catalytically active at chromosome ends, HeLa cells were treated with 10 µM CPT for 1 hr and subjected to TRF analysis (21) . DNA was recovered from the CsCl gradient and digested with HaeIII which liberates the TRF, followed by SDS-K + precipitation. To detect CPT-mediated DNA breaks on G-rich telomeric strand, the SDS-K + supernatants (which is depleted of topo I/DNA complexes) and precipitates (topo I-bound DNA) were digested with proteinase K, loaded on an alkaline agarose gel, and analyzed by Southern blotting using (CCCTAA) 4 oligonucleotide as a probe.
The TRFs from the SDS-K + supernatants display size heterogeneity since their length varies for the different chromosomes (Fig. 6A, lanes 1-3) (Fig. 6A, lane 5) . A TRF hybridization signal of etoposide-treated sample was roughly 3-5 times less (different experiments) than that of CPT-treated cells (Fig. 6A , compare lanes 5 and 6), suggesting that CPT induces higher DNA cleavages on telomeric repeats than etoposide.
When the DNA fractions were digested with proteinase K before SDS-K + precipitation, we observed no hybridization signal in the SDS-K + precipitates even in the longer exposure (Fig.   6B ). Telomeres are distinctive protein-DNA caps that distinguish chromosome ends from double-strand breaks in the genome (14, 15) . Chromatin structures at distal telomere regions are nuclease hypersensitive and appear to have altered nucleosome repeat intervals compared to bulk chromatin (22) . Nuclease hypersensitivity indicates that the chromatin structure is highly accessible to trans-acting factors, such as topo I, which is consistent with our mapping data. Our data are also consistent with cleavage activity along the entire length of the telomere; however, we cannot conclude that topo I acts within the t loop (19) (nor can we rule it out at this time). Our in vitro data demonstrate that CPT treatment causes the formation of topo I/DNA covalent complex at each G-rich telomeric repeat. Our in vivo experiments were not conducted at the level of single nucleotide resolution; therefore we cannot state definitively that the in vivo cut site is at the same exact nucleotide demonstrated by sequencing data with purified enzyme. Based on consensus sequence homology, however, it seems very likely that the in vitro and in vivo sites are coincident down to the nucleotide (see Fig. 1B ). In addition to sequence selectivity, topo I has been shown to preferentially recognize and cleave bent DNA (30, 31) . The bent helix conformation of the t loop might represent an attractive, high affinity binding region for topo I, although we cannot conclude that topo I is acting in t loops as noted above.
The physiological role of topo I in telomere function is not known. Topo I participates in post-DNA damage response, and distortions in helix such as DNA mismatches, abasic sites, and UV photoproducts trap topo I cleavable complexes in vivo in the absence of CPT (27, 32) .
Furthermore, the topo I/DNA damage response is dependent on cell cycle checkpoints activated by p53 after UV-damaged DNA (28) . These results suggest that topo I is a specific DNA damage site-nicking enzyme and a repair-proficient topoisomerase in vivo. Based on these observations, our data demonstrating the presence of topo I activity at telomeric regions in vivo suggest that topo I may play a role in DNA repair processing in response to endogenous telomere DNA damage.
We hypothesize that DNA damage at telomeric repeats by topo I is a prominent feature of apoptosis by CPT (Fig. 7) . This is consistent with a recent report that telomere loss occurs at early stages of CPT-induced apoptosis (33). Although CPT-induced DNA damage occurs at many sites throughout the genome, the telomere repeats may in fact be favoured. In addition C+T A+G CPT coralyne no drug
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